The contractual control arrangements read like every other VIE in the sector. Nobody had checked whether they'd actually hold up if the founder disagreed with them.
Sector
Biotech / Licensing
Stage
Series B
Geography
Hangzhou, VIE structure
Check Size
$20–30M range
What the Data Room Showed
The company operated in a sub-sector with foreign-ownership restrictions, so a VIE structure was expected and unremarkable on its face, consistent with the majority of foreign-invested companies in adjacent sub-sectors of the healthcare space, and the presence of the structure itself did not draw particular scrutiny from the deal team beyond the standard confirmation that it existed and was properly registered.
The VIE agreements followed a standard template used widely across the sector, prepared by a well-known international law firm's China practice, and legal diligence confirmed the documents were properly executed and registered with the relevant authorities, with all signature pages, corporate chops, and registration certificates present and internally consistent across the full document set.
The company's core asset, a licensed drug candidate in mid-stage clinical development with a domestic pharmaceutical partner, was well regarded within the sector, and the scientific diligence conducted by the lead investor's in-house medical team was strongly positive on both the clinical data generated to date and the regulatory pathway the candidate was pursuing.
The Structural Read
Governance
The founder retained unilateral authority to amend key VIE agreements
1 clause
Permitted operational amendments without investor consent
One clause, present in the template but rarely scrutinized in practice, gave the domestic founder-controlled entity the ability to amend certain operational agreements without investor consent, provided the amendments didn't alter economic terms directly. This created a path to gradually shift operational control without triggering the protective provisions investors would expect to catch it, since the amendment mechanism was framed narrowly enough (operational, not economic) to sit outside the standard consent-rights language the shareholder agreement had negotiated.
Walking through a hypothetical sequence of individually modest operational amendments (adjusting service-agreement scope, reallocating specific operational responsibilities between the offshore and domestic entities) showed that, cumulatively and over a multi-year period, this mechanism could plausibly narrow the practical scope of what the offshore entity actually controlled, without any single amendment being large enough on its own to obviously warrant investor objection — a slow-erosion risk pattern that a point-in-time document review, focused on confirming the agreements existed and were properly executed, was not designed to surface.
Political Exposure
VIE enforceability in this sub-sector had recent, mixed precedent
Recent regulatory commentary had signaled closer scrutiny of VIE arrangements in disputed cases within adjacent healthcare sub-sectors, without a clear ruling directly on point for this company's specific license category, meaning the structure's enforceability, while standard, was less battle-tested than its widespread use might suggest, a distinction between "commonly used" and "judicially tested" that the sector's general comfort with VIE structures tends to blur together in practice.
Reviewing the small number of publicly available dispute outcomes involving VIE-adjacent healthcare licensing arrangements showed no case with a fact pattern close enough to this company's specific situation to draw a confident inference either way, meaning the honest assessment was genuine legal uncertainty rather than either a clean bill of health or an active warning sign — a distinction worth stating plainly rather than resolving into false confidence in either direction.
Capital Dependency
A single licensing relationship represented most near-term revenue
One out-licensing agreement with a domestic pharmaceutical partner accounted for the majority of projected near-term revenue, and that partner was itself state-affiliated, meaning the same relationship carried both a capital-dependency concentration risk and a layer of political-exposure risk that compounded rather than diversified, since a dispute or relationship breakdown with this single partner would simultaneously remove the company's primary near-term revenue source and remove its primary channel for the kind of state-level regulatory goodwill that mid-stage biotech development in China commonly benefits from.
Examining the licensing agreement's own termination and dispute-resolution provisions showed the governing dispute-resolution venue was a domestic arbitration body rather than an internationally recognized neutral venue such as HKIAC or SIAC, meaning that in the event of a dispute with this specific partner, the foreign investor's practical leverage would be shaped by a venue with less international enforceability track record than the structures more commonly recommended for cross-border deals of this kind.
The Structural Report Outcome
Rather than treating VIE presence as a checkbox, the report priced in the specific amendment clause as a governance gap and recommended it be closed contractually before signing, distinct from the broader question of VIE enforceability, which remained a structural risk the committee would carry for the life of the investment regardless of what was negotiated.
On the enforceability precedent question, the report presented the genuine ambiguity in the available case law directly rather than rounding it up or down into false confidence, framing it as a risk the committee should weigh as an ongoing feature of the investment's risk profile rather than a diligence item that could be fully resolved before closing.
On the licensing-partner concentration and its non-neutral dispute-resolution venue, the report recommended the committee specifically negotiate for either a revised arbitration clause routing future disputes through HKIAC or SIAC, or, if that proved unavailable given the partner's own negotiating position, an explicit acknowledgment in the investment memo that this residual risk had been identified and knowingly accepted rather than overlooked.
The committee proceeded with the investment, successfully renegotiated the VIE amendment clause to require investor consent for the specific category of operational changes identified, but was unable to move the licensing partner off the domestic arbitration venue and instead documented that risk explicitly as an accepted, monitored exposure in its own investment memo — the outcome the structural report exists to make possible: not a guarantee against risk, but a clear-eyed, documented choice about which risks to accept and which to negotiate away.
ZINVEO ne décide pas. ZINVEO expose l'asymétrie structurelle. La décision finale revient
au comité d'investissement.
Recherchez dans notre couverture, ou demandez un accès direct au moteur de risque structurel de ZINVEO.
